A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers

References

• Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–958.
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Wallace DV, Baroody F, et al., Workgroup Chair and Cochair. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119:489–511. e41.
   PubMed Web of Science ®Google Scholar
• Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998; 48:956–960.
   PubMed Web of Science ®Google Scholar
• Marttin E, Schipper NGM, Verhoef JC, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliver Rev. 1998;29:13–38.
   PubMed Web of Science ®Google Scholar
• Wong YC, Zuo Z. Intranasal delivery-modification of drug metabolism and brain disposition. Pharm Res. 2010; 27:1208–1223.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. Rockville (MD): US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2003. https://www.fda.gov/media/70867/download
   Google Scholar
• Liu Q, Absar M, Saluja B, et al. Scientific considerations for the review and approval of first generic mometasone furoate nasal suspension spray in the United States from the bioequivalence perspective. AAPS J. 2019; 21:14
   PubMed Web of Science ®Google Scholar
• Kågedal M, Zingmark PH, Hedlund C, et al. True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers. Am J Adv Drug Deliv. 2005; 3:133–140.
   Google Scholar
• Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001; 108:S26–S31.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008; 63:1292–1300.
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharms. Rhinocort® AquaTM (budesonide) [package insert]. U.S. Food and Drug Administration. [revised 1999 Aug 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20746lbl.pdf
   Google Scholar
• Dimova H, Wang Y, Pommery S, et al. SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma. Biomed Chromatogr. 2003; 17:14–20.
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Fröehlich P, Hochhaus R, et al. A selective HPLC/RIA for the determination of budesonide. J Pharmaceut Biomed. 1998; 17:1235–1242.
   PubMed Web of Science ®Google Scholar
• Pujos E, Flament-Waton MM, Paisse O, et al. Comparison of the analysis of corticosteroids using different techniques. Anal Bioanal Chem. 2005; 381:244–254.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Atia NN. Controlled microwave derivatization reaction for reproducible trace analysis of budesonide in human plasma. Anal Chim Acta. 2019; 1048:132–142.
   PubMed Web of Science ®Google Scholar
• Rower JE, Anderson DJ, Sherwin CM, et al. Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. J Pharm Biomed Anal. 2019; 167:7–14.
   PubMed Web of Science ®Google Scholar
• Draft ICH guideline M10 on bioanalytical method validation. European Medicines Agency Committee for human medicinal products. Available from: https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation
   Google Scholar
• Szeitz A, Manji J, Riggs KW, et al. Validated assay for the simultaneous determination of cortisol and budesonide in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014; 90:198–206.
   PubMed Web of Science ®Google Scholar
• Lu Y, Sun Z, Zhang Y, et al. Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography–tandem mass spectrometry: application in a stereoselective pharmacokinetic study. J Chromatogr B. 2013;921-922:27–34.
   PubMed Web of Science ®Google Scholar
• do Carmo Borges NC, Astigarraga RB, Sverdloff CE, et al. Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879:236–242.
   PubMedGoogle Scholar
• Wang Y, Tang Y, Moellmann H, et al. Simultaneous quantification of budesonide and its two metabolites, 6β‐hydroxybudesonide and 16α‐hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. Biomed Chromatogr. 2003; 17:158–164.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Andersson M, Beck O. Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC–MS/MS. J Chromatogr B. 2014; 970:31–35.
   PubMed Web of Science ®Google Scholar
• Kronkvist K, Gustavsson M, Wendel AK, et al. Automated sample preparation for the determination of budesonide in plasma samples by liquid chromatography and tandem mass spectrometry. J Chromatogr A. 1998; 823:401–409.
   PubMed Web of Science ®Google Scholar
• Li YNB, Tattam B, Brown KF, et al. Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography–atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B. 2001; 761:177–185.
   PubMedGoogle Scholar
• Streel B, Cahay B, Klinkenberg R. Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877:2290–2300.
   PubMedGoogle Scholar
• Al-Numani D, Colucci P, Ducharme MP. Rethinking bioequivalence and equivalence requirements of orally inhaled drug products. Asian J Pharm Sci. 2015; 10:461–471.
   Web of Science ®Google Scholar
• Lähelmä S, Kirjavainen M, Kela M, et al. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol. 2005; 59:167–173.
   PubMed Web of Science ®Google Scholar
• Oliveira P, Fortuna A, Alves G, et al. Drug-metabolizing enzymes and efflux transporters in nasal epithelium: influence on the bioavailability of intranasally administered drugs. Curr Drug Metab. 2016; 17:628–647.
   PubMed Web of Science ®Google Scholar